Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 186M 161M 151M 138M 261M 17.69B 264M 1.77B 693M 8.84B 697M 682M 29.42B P/E 2026 *
-1.16x
P/E 2027 * -1.85x
Enterprise Value 186M 161M 151M 138M 261M 17.69B 264M 1.77B 693M 8.84B 697M 682M 29.42B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 2.35x
Free-Float
99.86%
Yield 2026 *
-
Yield 2027 * -
08-03 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
07-21 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
07-13 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
07-13 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
06-29 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
06-29 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
06-25 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
05-28 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
05-27 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
05-26 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI

Last Transcript: Tonix Pharmaceuticals Holding Corp

Manager TitleAgeSince
Chief Executive Officer 68 15/11/2007
Director of Finance/CFO 52 31/01/2016
Chief Tech/Sci/R&D Officer 57 03/02/2025
Director TitleAgeSince
Chairman 68 30/09/2011
Director/Board Member 66 11/09/2017
Director/Board Member 81 04/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+3.20%+59.70%+165.18% 1,062B
-0.24%+0.45%+50.64%+52.02% 619B
-0.95%-5.26%+24.23%+65.08% 431B
+2.40%+5.60%+49.90%+40.99% 358B
+0.90%-0.22%+35.75%+40.59% 293B
+1.43%-4.91%+9.70%+10.34% 247B
-0.73%+4.44%+42.22%+66.41% 219B
+4.87%+0.33%-0.44%-43.65% 200B
-0.68%-0.32%+18.66%+66.32% 162B
Average +0.69%-1.90%+32.26%+51.48% 399.14B
Weighted average by Cap. +0.22%-0.83%+41.24%+78.35%

Financials

2026 *2027 *
Net sales 34.18M 29.67M 27.78M 25.41M 47.97M 3.26B 48.6M 325M 128M 1.63B 128M 126M 5.42B 78.93M 68.5M 64.14M 58.67M 111M 7.52B 112M 750M 294M 3.76B 296M 290M 12.5B
Net income -170M -147M -138M -126M -239M -16.19B -242M -1.62B -634M -8.09B -638M -624M -26.93B -152M -132M -123M -113M -213M -14.46B -216M -1.44B -566M -7.23B -570M -558M -24.05B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-